Comparing Ribociclib and Palbociclib
Chapter 5In this video, Antonio C. Wolff, MD, professor of oncology at Johns Hopkins University in Baltimore, Maryland, notes whether there are any differences between ribociclib and palbociclib–use, particularly when combined with other medications. Dr Wolff also describes some methods and research around drug combinations with CDK4/6 inhibition.
The Role of Cell Cycle in Breast Cancer Progression
In this video, Antonio C. Wolff, MD, professor of oncology at Johns Hopkins University in Baltimore, Maryland, explains some of the processes of the normal cell cycle, as well as how this cycle is distorted to allow for cancer cell proliferation.
How Cyclin D Plays A Role in Breast Cancer Proliferation
In this video, Antonio C. Wolff, MD, professor of oncology at Johns Hopkins University in Baltimore, Maryland, describes how cyclin D plays a role in the development and progression of breast cancer.
The Potential of CDK4/6 Inhibitors for Breast Cancer Treatment
In this video, Antonio C. Wolff, MD, professor of oncology at Johns Hopkins University in Baltimore, Maryland, explains how CDK4/6 inhibitors can be used and combined with other treatments to effectively treat breast cancer.
Clinical Trial Data Regarding Ribociclib, Abemaciclib, and Palbociclib
In this video, Antonio C. Wolff, MD, professor of oncology at Johns Hopkins University in Baltimore, Maryland, describes some clinical trial data and adverse events noted in patients receiving a CDK4/6 inhibitor.
Drug Resistance to CDK4/6 Inhibitors
In this video, Antonio C. Wolff, MD, professor of oncology at Johns Hopkins University in Baltimore, Maryland, describes some data and research about mechanisms of resistance to CDK4/6 inhibition.
